New York, USA - March 1, 2010, New York, USA - Pfizer Inc. announced that William Ringo will retire from the company, effective April 30.
Article continues below
Prior to joining Pfizer in April 2008, Mr. Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From 2004 to 2006, he was President and CEO of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases.
From 2001 to 2004, he served on various boards – including the board of Encysive Pharmaceuticals, which Pfizer recently acquired – and was associated with Intermune, where he was appointed interim chief executive officer to help restructure the company and recruit new operational leadership.
Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure there he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001.
Mr. Ringo who holds a B.S. in Business Administration and an M.B.A. form the University of Dayton – serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region.
Kristin Peck, who will succeed Mr. Ringo, has been named Senior Vice President of Worldwide Business Development, Strategy and Innovation. Most recently, she played a leadership role in the integration of Wyeth’s global operations, while serving as Senior Vice President of Worldwide Strategy and Innovation.
Ms. Peck joined Pfizer in 2004 in the company’s strategic planning organization. Prior to Pfizer, she was a principal with the Boston Consulting Group, focusing on strategy and merger-related issues in the pharmaceutical and financial services industries, and worked in real estate financial services and private equity at Prudential and The O’Connor Group. ■